ACT Capital Management’s Clearside Biomedical CLSD Stock Holding History

ACT Capital Management’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$2.48M	Sell	146,499 -6,048	-4%	-$132K	3.43%	10
2022 Q2	$3.36M	Sell	152,547 -11,360	-7%	-$276K	4.7%	7
2022 Q1	$5.63M	Sell	163,907 -1,660	-1%	-$49.7K	5.96%	4
2021 Q4	$6.83M	Buy	165,567 +1,067	+0.6%	+$69.1K	4.94%	4
2021 Q3	$14.8M	Buy	164,500 +333	+0.2%	+$29.4K	7.67%	3
2021 Q2	$12M	Buy	+164,167	New	+$7.63M	6.16%	4

Other funds holding CLSD

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

ACT Capital Management's CLSD Position: Q3 2022 in Review

ACT Capital Management reduced its Clearside Biomedical (CLSD) stake by 4% in Q3 2022, selling an estimated $132K and leaving 146,499 shares worth $2.48M. The position accounts for 3.43% of the portfolio, ranked #10.

ACT Capital Management first reported a position in CLSD in Q2 2021 and has held it in 6 quarters since. The position peaked at $14.8M in Q3 2021. 54 funds tracked by Wall St. Rank hold CLSD as of Q3 2022.

ACT Capital Management held 146,499 shares of Clearside Biomedical worth $2.48M as of Q3 2022.
ACT Capital Management sold 6,048 Clearside Biomedical shares in Q3 2022, an estimated $132K.
Clearside Biomedical made up 3.43% of ACT Capital Management's portfolio in Q3 2022, its #10 holding.
ACT Capital Management first reported a position in Clearside Biomedical in Q2 2021 and has held it in 6 quarters since.
ACT Capital Management's Clearside Biomedical position peaked at $14.8M in Q3 2021.
54 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.